William E. Duke - 23 May 2023 Form 4 Insider Report for Apexigen, Inc.

Role
Chief Financial Officer
Signature
/s/ Francis Sarena, by power of attorney
Issuer symbol
N/A
Transactions as of
23 May 2023
Net transactions value
-$6,904
Form type
4
Filing time
25 May 2023, 16:21:23 UTC
Previous filing
19 Dec 2022
Next filing
23 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APGN Common Stock Award $0 +150,000 +573% $0.000000 176,182 23 May 2023 Direct F1
transaction APGN Common Stock Tax liability $6,904 -17,261 -9.8% $0.4000 158,921 23 May 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported shares are represented by restricted stock units, or RSUs. Upon signing of the merger agreement between the Issuer and Pyxis Oncology, Inc. dated May 23, 2023, 60,000 RSUs vested. The remaining 90,000 RSUs vest on the earlier of (i) the closing of the merger or (ii) September 30, 2023.
F2 The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of RSUs.